Back to top

Acrivon Therapeutics downgraded to Hold from Buy at JonesResearch

JonesResearch downgraded Acrivon Therapeutics (ACRV) to Hold from Buy without a price target Investors may now be focused on ACR-2316 as a way to r...

Read full article here »

In-Depth Zacks Research for the Tickers Above

Normally $25 each - click below to receive one report FREE:

Acrivon Therapeutics, Inc. (ACRV)